Spotlight On... Celgene buries the hatchet with India's Natco over generic Revlimid; Turing's crisis comms group scrambles; NICE backs Velcade, SGLT2 meds for new uses; Sanofi submits LixiLan to FDA; and more...

Celgene ($CELG) is getting in the holiday spirit, settling its Revlimid patent fight with Indian generics maker Natco. Under the settlement, Celgene will let Natco roll out copycat versions of its $5 billion bestseller starting in 2022, as long as Natco agrees to a "volume-limit license." The license restricts the amount of capsules Natco can sell, giving Celgene some breathing room before Natco's full launch in 2026. More from FiercePharma

> Turing Pharmaceuticals isn't going it alone in the PR battle touched off by pharma bad boy Martin Shkreli, its now-ex-CEO; DCI Group signed on several months ago and is helping manage crisis communications. Report

> U.K. cost-effectiveness watchdogs backed Johnson & Johnson's ($JNJ) Velcade in mantle cell lymphoma, and three SGLT2 diabetes drugs--J&J's Invokana, AstraZeneca's ($AZN) Forxiga and Eli Lilly & Co. ($LLY) and Boehringer Ingelheim's Jardiance--as monotherapies in certain patients. Report

> Sanofi ($SNY) submitted its insulin-plus-GLP-1 diabetes drug LixiLan to the FDA, hoping for an approval next year; one half of that med, the GLP-1 Lyxumia, is awaiting an FDA nod now. Release | More

> Merck KGaA and Pfizer ($PFE) are pushing ahead with two new late-stage studies for avelumab, a PD-L1 cancer med that's playing catch-up in the immuno-oncology field. Report

And Finally... Public health officials are pushing for wider use of a Gilead Sciences ($GILD) drug to prevent HIV infection, but some AIDS groups continue to oppose it. Report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.